-
Company Developing PAH Therapy Secures $34M in Funding
PhaseBio Pharmaceuticals has secured $34 million in financing to advance the clinical development of PB1046, a potential treatment for PAH, among others.
Click here to read more about this story.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.